Literature DB >> 20716959

Engineering host cell lines to reduce terminal sialylation of secreted antibodies.

Michael F Naso1, Susan H Tam, Bernard J Scallon, T Shantha Raju.   

Abstract

Covalently-linked glycans on proteins have many functional roles, some of which are still not completely understood. Antibodies have a very specific glycan modification in the Fc region that is required for mediating immune effector functions. These Fc glycans are typically highly heterogeneous in structure, and this heterogeneity is influenced by many factors, such as type of cellular host and rate of Ab secretion. Glycan heterogeneity can affect the Fc-dependent activities of antibodies. It has been shown recently that increased Fc sialylation can result in decreased binding to immobilized antigens and some Fcγ receptors, as well as decreased antibody-dependent cell-mediated cytotoxicity (ADCC) activity. In contrast, increased Fc sialylation enhances the anti-inflammatory activity of antibodies. To produce antibodies with increased effector functions, we developed host cell lines that would limit the degree of sialylation of recombinantly-expressed antibodies. Towards this end, the catalytic domain of the Arthrobacter ureafaciens sialidase (sialidase A) was engineered for secreted expression in mammalian cell lines. Expression of this sialidase A gene in mammalian cells resulted in secreted expression of soluble enzyme that was capable of removing sialic acid from antibodies secreted into the medium. Purified antibodies secreted from these cells were found to possess very low levels of sialylation compared with the same antibodies purified from unmodified host cells. The low sialylated antibodies exhibited similar binding affinity to soluble antigens, improved ADCC activity, and they possessed pharmacokinetic properties comparable to their more sialylated counterparts. Further, it was observed that the amount of sialidase A expressed was sufficient to thoroughly remove sialic acid from Abs made in high-producing cell lines. Thus, engineering host cells to express sialidase A enzyme can be used to produce recombinant antibodies with very low levels of sialylation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20716959      PMCID: PMC2958573          DOI: 10.4161/mabs.2.5.13078

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  22 in total

Review 1.  Enhancing therapeutic glycoprotein production in Chinese hamster ovary cells by metabolic engineering endogenous gene control with antisense DNA and gene targeting.

Authors:  T G Warner
Journal:  Glycobiology       Date:  1999-09       Impact factor: 4.313

Review 2.  Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals.

Authors:  Michael Butler
Journal:  Appl Microbiol Biotechnol       Date:  2005-04-16       Impact factor: 4.813

3.  Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain.

Authors:  T Shantha Raju; Bernard J Scallon
Journal:  Biochem Biophys Res Commun       Date:  2006-01-19       Impact factor: 3.575

Review 4.  Optimal and consistent protein glycosylation in mammalian cell culture.

Authors:  Patrick Hossler; Sarwat F Khattak; Zheng Jian Li
Journal:  Glycobiology       Date:  2009-06-03       Impact factor: 4.313

Review 5.  Effect of glycosylation on antibody function: implications for genetic engineering.

Authors:  A Wright; S L Morrison
Journal:  Trends Biotechnol       Date:  1997-01       Impact factor: 19.536

Review 6.  The asialoglycoprotein receptor: relationships between structure, function, and expression.

Authors:  R J Stockert
Journal:  Physiol Rev       Date:  1995-07       Impact factor: 37.312

7.  A role for pneumolysin but not neuraminidase in the hearing loss and cochlear damage induced by experimental pneumococcal meningitis in guinea pigs.

Authors:  A J Winter; S D Comis; M P Osborne; M J Tarlow; J Stephen; P W Andrew; J Hill; T J Mitchell
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

Review 8.  Comparative enzymology, biochemistry and pathophysiology of human exo-alpha-sialidases (neuraminidases).

Authors:  K E Achyuthan; A M Achyuthan
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2001-05       Impact factor: 2.231

9.  Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics.

Authors:  T S Raju; J B Briggs; S M Borge; A J Jones
Journal:  Glycobiology       Date:  2000-05       Impact factor: 4.313

10.  Cloning, expression and characterization of a sialidase gene from Arthrobacter ureafaciens.

Authors:  Søren Christensen; Jan Egebjerg
Journal:  Biotechnol Appl Biochem       Date:  2005-06       Impact factor: 2.431

View more
  20 in total

1.  An innovative approach for the characterization of the isoforms of a monoclonal antibody product.

Authors:  Shanmuuga Sundaram; Alice Matathia; Jun Qian; Jingming Zhang; Ming-Ching Hsieh; Tun Liu; Richard Crowley; Babita Parekh; Qinwei Zhou
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

2.  Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability.

Authors:  Frederick W Jacobsen; Riki Stevenson; Cynthia Li; Hossein Salimi-Moosavi; Ling Liu; Jie Wen; Quanzhou Luo; Kristine Daris; Lynette Buck; Sterling Miller; Shu-Yin Ho; Wei Wang; Qing Chen; Kenneth Walker; Jette Wypych; Linda Narhi; Kannan Gunasekaran
Journal:  J Biol Chem       Date:  2016-12-19       Impact factor: 5.157

Review 3.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.

Authors:  David J Harvey
Journal:  Mass Spectrom Rev       Date:  2014-05-26       Impact factor: 10.946

Review 4.  Analytical comparability study of recombinant monoclonal antibody therapeutics.

Authors:  Alexandre Ambrogelly; Stephen Gozo; Amit Katiyar; Shara Dellatore; Yune Kune; Ram Bhat; Joanne Sun; Ning Li; Dongdong Wang; Christine Nowak; Alyssa Neill; Gomathinayagam Ponniah; Cory King; Bruce Mason; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-03-20       Impact factor: 5.857

5.  Metabolic monosaccharides altered cell responses to anticancer drugs.

Authors:  Long Chen; Jun F Liang
Journal:  Eur J Pharm Biopharm       Date:  2012-04-02       Impact factor: 5.571

6.  Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases.

Authors:  Ziyang Xu; Michelle Ho; Devivasha Bordoloi; Sagar Kudchodkar; Makan Khoshnejad; Leila Giron; Faraz Zaidi; Moonsup Jeong; Christine C Roberts; Young K Park; Joel Maslow; Mohamed Abdel-Mohsen; Kar Muthumani
Journal:  Methods Mol Biol       Date:  2022

Review 7.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

Review 8.  Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy.

Authors:  Christian Kellner; Anna Otte; Elisa Cappuzzello; Katja Klausz; Matthias Peipp
Journal:  Transfus Med Hemother       Date:  2017-09-08       Impact factor: 3.747

Review 9.  Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

10.  Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications.

Authors:  Xiaotian Zhong; Jill F Wright
Journal:  Int J Cell Biol       Date:  2013-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.